International Journal of Clinical Pharmacy

, Volume 34, Issue 3, pp 426–431 | Cite as

Characteristics of HIV patients referred to a medication adherence program in Switzerland

  • Isabelle Krummenacher
  • Matthias Cavassini
  • Olivier Bugnon
  • Marie P. SchneiderEmail author
Short Research Report


Background Since August 2004, HIV patients who encounter -or are at risk of -problems with their antiretroviral treatment (ART) are referred by their physician to a medication adherence program at the community pharmacy of the Department of Ambulatory Care and Community Medicine in Lausanne (Switzerland). The program combines motivational interviewing and electronic drug monitoring. Objective To compare the demographic and clinical characteristics as well as ART of HIV patients referred to the adherence program versus those of the entire HIV population followed in the same infection disease department in the same time frame. Method Retrospective descriptive cross-sectional study. Study time frame was defined according to the period with the highest number of HIV patients visiting the adherence program. Results Subjects included in the adherence program had more often a protease inhibitor-based regimen (64 %; 95 % CI [52–75 %] vs. 37 %) and lower CD4 cell counts (419 (252.0, 521.0); 95 % CI [305–472] vs. 500 (351.0, 720.0)) than the entire HIV population. A majority of women were included in the adherence program (66 %; 95 % CI [54–76 %] vs. 39% in the entire HIV population). Conclusion Subjects referred to the adherence program were different from the entire HIV population and showed worse clinical outcomes and were more often under salvage therapy. More women than men were included. Reasons for such a difference need to be further explored.


Adherence program Antiretroviral therapy Cross-sectional studies HIV Intervention Medication adherence Pharmacists Switzerland 



We acknowledge the members of the Swiss HIV Cohort Study for their support.



Conflicts of interest

Isabelle Krummenacher has no conflict of interest to declare. Matthias Cavassini received travel grants from Abbott and an unrestricted grant from Gilead. Olivier Bugnon received unrestricted grants from Abbott. Marie P. Schneider received a travel grant from Abbott and an unrestricted grant from Gilead.


  1. 1.
    American Public Health Association. Adherence to HIV treatment regimens: recommendations for best practices. [Internet]. 2004 June [cited 2011 May 18]. Available from:
  2. 2.
    Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003;17(13):1925–32.PubMedCrossRefGoogle Scholar
  3. 3.
    Glass TR, de Geest S, Hirschel B, Battegay M, Furrer H, Cavassini M, et al. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther. 2008;13(1):77–85.PubMedGoogle Scholar
  4. 4.
    Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15–22.PubMedCrossRefGoogle Scholar
  5. 5.
    Krummenacher I, Cavassini M, Bugnon O, Schneider MP. An interdisciplinary HIV-adherence program combining motivational interviewing and electronic antiretroviral drug monitoring. AIDS Care. 2011;23(5):550–61.PubMedCrossRefGoogle Scholar
  6. 6.
    Peretti-Watel P, Spire B, Schiltz MA, Bouhnik AD, Heard I, Lert F, et al. Vulnerability, unsafe sex and non-adherence to HAART: evidence from a large sample of French HIV/AIDS outpatients. Soc Sci Med. 2006;62(10):2420–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med. 2002;54(10):1481–96.PubMedCrossRefGoogle Scholar
  8. 8.
    Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19(2):124–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Graham J, Bennett IM, Holmes WC, Gross R. Medication beliefs as mediators of the health literacy-antiretroviral adherence relationship in HIV-infected individuals. AIDS Behav. 2007;11(3):385–92.PubMedCrossRefGoogle Scholar
  10. 10.
    Kalichman SC, Pope H, White D, Cherry C, Amaral CM, Swetzes C, et al. Association between health literacy and HIV treatment adherence: further evidence from objectively measured medication adherence. J Int Assoc Phys AIDS Care. 2008;7(6):317–23.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Isabelle Krummenacher
    • 1
  • Matthias Cavassini
    • 2
  • Olivier Bugnon
    • 1
    • 3
  • Marie P. Schneider
    • 3
    • 4
    Email author
  1. 1.Community Pharmacy Research Unit, Pharmaceutical Sciences SectionUniversities of Geneva and LausanneLausanneSwitzerland
  2. 2.Service of Infectious Disease, Centre HospitalierUniversitaire Vaudois, University of LausanneLausanneSwitzerland
  3. 3.Community Pharmacy, Department of Ambulatory Care and Community MedicineUniversity of LausanneLausanneSwitzerland
  4. 4.Community Pharmacy Research UnitPharmacie de la Policlinique Médicale UniversitaireLausanneSwitzerland

Personalised recommendations